Compare, Analyse ASTRAZENECA PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ACTAVIS (US) - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   ACTAVIS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ACTAVIS
Dec-18
ASTRAZENECA PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,27814,269-   
Low Rs8839,571-   
Sales per share (Unadj.) Rs228.43,500.1-  
Earnings per share (Unadj.) Rs10.4-1,127.4-  
Cash flow per share (Unadj.) Rs16.3368.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.814,436.3-  
Shares outstanding (eoy) m25.00332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.4 138.9%   
Avg P/E ratio x104.2-10.6 -985.8%  
P/CF ratio (eoy) x66.432.3 205.6%  
Price / Book Value ratio x10.90.8 1,324.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0083,964,616 0.7%   
No. of employees `0001.416.9 8.0%   
Total wages/salary Rs m1,5350-   
Avg. sales/employee Rs Th4,210.968,883.6 6.1%   
Avg. wages/employee Rs Th1,132.20-   
Avg. net profit/employee Rs Th191.1-22,187.4 -0.9%   
INCOME DATA
Net Sales Rs m5,7101,164,133 0.5%  
Other income Rs m12322,262 0.6%   
Total revenues Rs m5,8331,186,395 0.5%   
Gross profit Rs m46330,506 1.5%  
Depreciation Rs m147497,642 0.0%   
Interest Rs m067,177 0.0%   
Profit before tax Rs m438-512,051 -0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0130,594 0.0%   
Tax Rs m179-6,489 -2.8%   
Profit after tax Rs m259-374,968 -0.1%  
Gross profit margin %8.12.6 309.4%  
Effective tax rate %40.81.3 3,223.0%   
Net profit margin %4.5-32.2 -14.1%  
BALANCE SHEET DATA
Current assets Rs m3,209477,467 0.7%   
Current liabilities Rs m2,070422,383 0.5%   
Net working cap to sales %20.04.7 421.8%  
Current ratio x1.61.1 137.2%  
Inventory Days Days7220 369.3%  
Debtors Days Days3566 52.7%  
Net fixed assets Rs m790131,773 0.6%   
Share capital Rs m500-   
"Free" reserves Rs m2,4190-   
Net worth Rs m2,4694,801,506 0.1%   
Long term debt Rs m01,690,784 0.0%   
Total assets Rs m4,6057,505,847 0.1%  
Interest coverage xNM-6.6-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.20.2 799.4%   
Return on assets %5.6-4.1 -137.2%  
Return on equity %10.5-7.8 -134.4%  
Return on capital %17.7-4.8 -366.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,7150-   
CASH FLOW
From Operations Rs m88415,901 0.0%  
From Investments Rs m-94228,483 -0.0%  
From Financial Activity Rs mNA-713,811 0.0%  
Net Cashflow Rs m-6-69,080 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.74 Rs / USD

Compare ASTRAZENECA PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: IPCA LABS  DIVIS LABORATORIES  ALEMBIC PHARMA  GLENMARK PHARMA  NEULAND LABS  



Today's Market

Sensex Ends Flat; Maruti Suzuki Rallies 7.5%(Closing)

After opening the day at record high levels, Indian share markets erased gains as the session progressed and ended on a flat note, led by a decline in IT stocks and index heavyweight HDFC Bank.

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks (Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

It's Time to Book Profits (Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You (Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

Create Wealth for Yourself in India's Drone Revolution (Profit Hunter)

Nov 27, 2020

The Chinese drone market is 14 times that of India's. Billions may flow into Indian drone companies too. Don't miss out on this wealth creating opportunity.

The Price of Dying, the Cost of Living (The Honest Truth)

Nov 20, 2020

Ajit Dayal presents a cost benefit analysis of the various types of response to covid around the world.

More
-->

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

ASTRAZENECA PHARMA SHARE PRICE


Dec 3, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - GSK PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

FEATURED VIDEOS

Adani Green: A Future Multibagger or a Big, Speculative Bubble

Is M&M the ITC of Auto Sector?

Don't Let Brokerages Fool You into Buying HUL & Nestle. The Real Money is in These Stocks Right Now...

What to Expect from Stocks during Covid Second Wave?

More Featured Videos

MARKET STATS